menu
    • menu
    [{"orgOrder":0,"company":"Trio Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Netazepide","moa":"Cholecystokinin B receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Trio Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trio Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Trio Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Trio Medicines","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"YF476","moa":"Cholecystokinin B receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Trio Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trio Medicines \/ Ferring Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Trio Medicines \/ Ferring Pharmaceuticals"},{"orgOrder":0,"company":"Trio Medicines","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"YF476","moa":"Cholecystokinin B receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Trio Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trio Medicines \/ Ferring Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Trio Medicines \/ Ferring Pharmaceuticals"},{"orgOrder":0,"company":"Trio Medicines","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"YF476","moa":"Cholecystokinin B receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Trio Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trio Medicines \/ Ferring Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Trio Medicines \/ Ferring Pharmaceuticals"},{"orgOrder":0,"company":"Trio Medicines","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"YF476","moa":"Cholecystokinin B receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Trio Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trio Medicines \/ Ferring Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Trio Medicines \/ Ferring Pharmaceuticals"},{"orgOrder":0,"company":"Trio Medicines","sponsor":"James Black Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"YF476","moa":"Cholecystokinin B receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Trio Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trio Medicines \/ James Black Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Trio Medicines \/ James Black Foundation"},{"orgOrder":0,"company":"Trio Medicines","sponsor":"James Black Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"YF476","moa":"Cholecystokinin B receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Trio Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trio Medicines \/ James Black Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Trio Medicines \/ James Black Foundation"},{"orgOrder":0,"company":"Trio Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"YF476","moa":"Cholecystokinin B receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Trio Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trio Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Trio Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Trio Medicines","sponsor":"Royal Liverpool University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"YF476","moa":"Cholecystokinin B receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Trio Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trio Medicines \/ Royal Liverpool University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Trio Medicines \/ Royal Liverpool University Hospital"},{"orgOrder":0,"company":"Trio Medicines","sponsor":"Norwegian University of Science and Technology","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"YF476","moa":"Cholecystokinin B receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Trio Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trio Medicines \/ Norwegian University of Science and Technology","highestDevelopmentStatusID":"8","companyTruncated":"Trio Medicines \/ Norwegian University of Science and Technology"},{"orgOrder":0,"company":"Trio Medicines","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"YF476","moa":"Cholecystokinin B receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Trio Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trio Medicines \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Trio Medicines \/ National Institutes of Health"},{"orgOrder":0,"company":"Trio Medicines","sponsor":"Columbia University | University of Cambridge","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"YF476","moa":"Cholecystokinin B receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Trio Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trio Medicines \/ Columbia University | University of Cambridge","highestDevelopmentStatusID":"8","companyTruncated":"Trio Medicines \/ Columbia University | University of Cambridge"},{"orgOrder":0,"company":"Trio Medicines","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Trio Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trio Medicines \/ Biogen","highestDevelopmentStatusID":"6","companyTruncated":"Trio Medicines \/ Biogen"},{"orgOrder":0,"company":"Trio Medicines","sponsor":"Hammersmith Medicines Research","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"TR4","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trio Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trio Medicines \/ Hammersmith Medicines Research","highestDevelopmentStatusID":"8","companyTruncated":"Trio Medicines \/ Hammersmith Medicines Research"}]

    Find Clinical Drug Pipeline Developments & Deals by Trio Medicines

    Menu

    Trio Medicines

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Trio Medicines

                            United Kingdom arrow
                            VMX
                            Not Confirmed

                            Trio Medicines

                            United Kingdom arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TR4

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Hammersmith Medicines Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Selective β2-AR Antagonism in Asthma

                            Details : TR4 is a small molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Asthma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 09, 2025

                            Lead Product(s) : TR4

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Hammersmith Medicines Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Trio Medicines

                            United Kingdom arrow
                            VMX
                            Not Confirmed

                            Trio Medicines

                            United Kingdom arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Netazepide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Netazepide on Omeprazole-induced Changes in Chromogranin A and Gastrin

                            Details : Netazepide is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of ECL-cell Hyperplasia.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 03, 2015

                            Lead Product(s) : Netazepide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Trio Medicines

                            United Kingdom arrow
                            VMX
                            Not Confirmed

                            Trio Medicines

                            United Kingdom arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YF476

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Columbia University | University of Cambridge

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            YF476 in Barrett's Esophagus

                            Details : YF476 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Barrett Esophagus.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            November 05, 2015

                            Lead Product(s) : YF476

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Columbia University | University of Cambridge

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Trio Medicines

                            United Kingdom arrow
                            VMX
                            Not Confirmed

                            Trio Medicines

                            United Kingdom arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YF476

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Sponsor : National Institutes of Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            YF476 and Type II Gastric Carcinoids

                            Details : YF476 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Zollinger-Ellison Syndrome.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            May 27, 2015

                            Lead Product(s) : YF476

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Sponsor : National Institutes of Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Trio Medicines

                            United Kingdom arrow
                            VMX
                            Not Confirmed

                            Trio Medicines

                            United Kingdom arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interferon Beta-1A

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Biogen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Avonex®: Safety, Blood Levels and Effects

                            Details : Interferon Beta-1a is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Multiple Sclerosis.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            May 27, 2013

                            Lead Product(s) : Interferon Beta-1A

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Biogen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Trio Medicines

                            United Kingdom arrow
                            VMX
                            Not Confirmed

                            Trio Medicines

                            United Kingdom arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YF476,Rabeprazole Sodium

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effects of YF476 and Rabeprazole on Gastric Function

                            Details : YF476 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hypergastrinaemia.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 03, 2012

                            Lead Product(s) : YF476,Rabeprazole Sodium

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Trio Medicines

                            United Kingdom arrow
                            VMX
                            Not Confirmed

                            Trio Medicines

                            United Kingdom arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YF476

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : James Black Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Repeated Doses of YF476 on Stomach Acidity

                            Details : YF476 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hypergastrinaemia.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            May 18, 2012

                            Lead Product(s) : YF476

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : James Black Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Trio Medicines

                            United Kingdom arrow
                            VMX
                            Not Confirmed

                            Trio Medicines

                            United Kingdom arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YF476

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : James Black Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Single Doses of YF476 on Stomach Acidity

                            Details : YF476 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hypergastrinaemia.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            May 18, 2012

                            Lead Product(s) : YF476

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : James Black Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Trio Medicines

                            United Kingdom arrow
                            VMX
                            Not Confirmed

                            Trio Medicines

                            United Kingdom arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YF476,Omeprazole

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Ferring Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Repeated Doses of YF476, Omeprazole and Placebo on Stomach Acidity in Healthy Volunteers

                            Details : YF476 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Esophagitis, Peptic.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            May 16, 2012

                            Lead Product(s) : YF476,Omeprazole

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Ferring Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Trio Medicines

                            United Kingdom arrow
                            VMX
                            Not Confirmed

                            Trio Medicines

                            United Kingdom arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YF476

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Ferring Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of 5, 10 or 25 mg of YF476 Daily for 14 Days on Stomach Acidity in Healthy Volunteers

                            Details : YF476 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Esophagitis, Peptic.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            May 14, 2012

                            Lead Product(s) : YF476

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Ferring Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.